forbes.com
May 13, 2008
Intercell is planning to acquire the needle-free immunization developer, Iomai, for $189.0 million, or $6.60 a share, in hopes of becoming the international traveler's best friend with a new portfolio of vaccines for voyagers. Shares of Iomai (nasdaq: )'s deal values Iomai's stock at a 126.0%...
[read full story]